Pharmaceutical Stocks
Top 10 of 25 PPH holdings, updated
As of 17 November 2026, pharmaceutical stocks are among the strongest groups in the market, well ahead of the S&P 500. PPH beats the S&P 500 by 9.0 points over one month and ranks #6 of 115 groups Zensei tracks. 10 of the 23 pharmaceutical stocks Zensei prices in PPH beat the fund this month.
Where pharmaceutical stocks stand now
As of 17 November 2026, Pharmaceutical (PPH) ranks #6 of the 115 groups Zensei tracks by one-month return against the S&P 500, inside the top tier of the market. It sits in the Outperformers quadrant of the rotation map: it has decisively beaten the S&P 500 by 9.0 points over the past month, on top of a 1.7-point advantage over the longer, time-shifted window.
On the shorter tape, PPH's momentum is weakening: the intraday trend that carried the move is cooling across the shorter windows. PPH's relative-strength line — its price ratio against the S&P 500 — is trading above its moving averages, the healthiest configuration we track. The longer trend remains healthier than the recent tape suggests — the kind of divergence worth rechecking in a week.
The exposure comes via VanEck Pharmaceutical ETF, whose 25 tracked holdings are led by Eli Lilly and Co, Merck & Co Inc and Novo Nordisk As. Weighted by portfolio, the fund's holdings trade at roughly 29.4× earnings. The thing to watch from here is durability: outperformers that hold their one-month spread while the longer window keeps building tend to stay out front; a fading spread is the early exit signal.
Top pharmaceutical stocks right now
The largest pharmaceutical stocks by weight in PPH, and the strongest over the past month. Size and recent return are measurements, not recommendations.
Largest by fund weight
Share of PPH
- 1Eli Lilly and CoLLY23.2%
- 2Merck & Co IncMRK12.5%
- 3Novo Nordisk AsNVO5.5%
- 4Pfizer IncPFE5.1%
- 5Mckesson CorpMCK4.7%
Strongest this month
1-month return, holdings Zensei prices
- 1Sanofi SASNY+17.0%
- 2Jazz Pharmaceuticals PLCJAZZ+14.5%
- 3Eli Lilly and CoLLY+12.7%
- 4Takeda Pharmaceutical Co LtdTAK+10.0%
- 5Elanco Animal Health IncELAN+9.8%
Pharmaceutical Stocks vs the S&P 500
Over the week to 17 November 2026, PPH fell 1.2% while the S&P 500 fell 2.3%. PPH and SPY (the S&P 500) over every window Zensei tracks. The spread is the difference: positive means PPH won that window.
Prices as of · computed from daily adjusted closes · how we measure
Pharmaceutical on the rotation map, against the 11 broad S&P 500 sectors. Vertical: 1-month spread vs the S&P 500. Horizontal: the longer, time-shifted window.
Are pharmaceutical stocks expensive?
The price-to-earnings ratio of PPH as a whole: the total price of its holdings over their total earnings, weighted by share of the fund. Holdings that lose money are left out.
PPH holdings: the pharmaceutical stocks inside
As of 17 November 2026, 10 of the 23 pharmaceutical stocks Zensei prices in PPH beat the fund over the past month. 18 of them beat the S&P 500. The strongest is Sanofi SA (SNY); the weakest is Corcept Therapeutics Inc (CORT). Inside the fund, the holdings split between winners and losers.
| # | Holding | Weight | 1M | 3M | vs fund 1M | Momentum | RS health |
|---|---|---|---|---|---|---|---|
| 1 | LLYEli Lilly and Co | 23.2% | +12.7% | +15.6% | +7.8 pts | Weak | Fading |
| 2 | MRKMerck & Co Inc | 12.5% | −1.8% | +6.7% | −6.7 pts | Weak | Broken |
| 3 | NVONovo Nordisk As | 5.5% | +4.8% | −11.0% | −0.2 pts | Weak | Broken |
| 4 | PFEPfizer Inc | 5.1% | −2.3% | +6.0% | |||
| 5 | MCKMckesson Corp | 4.7% | +8.6% | +25.7% | |||
| 6 | BMYBristol-Myers Squibb Co | 4.5% | +2.7% | −6.2% | |||
| 7 | Teva Pharmaceutical Industries Ltd | 4.5% | — | — | No price data | ||
| 8 | CORCencora Inc | 4.3% | +3.0% | +11.1% | |||
| 9 | GSKGsk PLC | 4.2% | +0.3% | −2.9% | |||
| 10 | Astrazeneca PLC | 3.8% | — | — | No price data | ||
All 25 PPH holdings by weight: Eli Lilly and Co (LLY) 23.2%, Merck & Co Inc (MRK) 12.5%, Novo Nordisk As (NVO) 5.5%, Pfizer Inc (PFE) 5.1%, Mckesson Corp (MCK) 4.7%, Bristol-Myers Squibb Co (BMY) 4.5%, Teva Pharmaceutical Industries Ltd 4.5%, Cencora Inc (COR) 4.3%, Gsk PLC (GSK) 4.2%, Astrazeneca PLC 3.8%, Novartis AG (NVS) 3.8%, Abbvie Inc (ABBV) 3.7%, Sanofi SA (SNY) 3.4%, Haleon PLC (HLN) 3.3%, Johnson & Johnson (JNJ) 3.2%, Takeda Pharmaceutical Co Ltd (TAK) 2.9%, Zoetis Inc (ZTS) 2.7%, Viatris Inc (VTRS) 1.5%, Jazz Pharmaceuticals PLC (JAZZ) 1.1%, Axsome Therapeutics Inc (AXSM) 0.5%, Corcept Therapeutics Inc (CORT) 0.5%, Elanco Animal Health Inc (ELAN) 0.5%, Definium Therapeutics Inc (DFTX) 0.4%, Organon & Co (OGN) 0.3%, Perrigo Co PLC (PRGO) 0.1%.
Pharmaceutical Stocks: common questions
What are the top 3 pharmaceutical stocks?
As of 17 November 2026, the three largest pharmaceutical stocks in PPH by fund weight are Eli Lilly and Co (LLY) (23.2%), Merck & Co Inc (MRK) (12.5%) and Novo Nordisk As (NVO) (5.5%). Fund weight shows size inside the fund, not a recommendation.
Which pharmaceutical stocks are beating the sector?
As of 17 November 2026, 10 of the 23 pharmaceutical stocks Zensei prices in PPH beat the fund over the past month. The strongest over the past month is Sanofi SA (SNY). The list above shows every holding with its weight and returns.
Are pharmaceutical stocks outperforming the S&P 500?
Yes. As of 17 November 2026, PPH has beaten the S&P 500 by 9.0 points over the past month.
Is it a good time to invest in pharmaceutical stocks?
Zensei does not give investment advice, but it measures the trend. As of 17 November 2026, pharmaceutical stocks are ahead of the S&P 500 on both the recent and the longer window. The rotation map and the read on this page show whether that trend is building or fading.
What is PPH?
PPH is VanEck Pharmaceutical ETF. Zensei uses it to measure pharmaceutical stocks against the S&P 500 (SPY).
What stocks does PPH own?
As of 17 November 2026, the largest of the 25 positions Zensei tracks in PPH are Eli Lilly and Co, Merck & Co Inc, Novo Nordisk As, Pfizer Inc, Mckesson Corp. Each position measured against the fund, with momentum and relative strength, is part of Zensei Premium.
What quadrant is pharmaceutical in right now?
As of 17 November 2026, pharmaceutical is in the Outperformers quadrant — outperforming the S&P 500 on both the recent and the longer, time-shifted window. The Zensei methodology page explains the quadrants.
Recent changes
- ·Gaining ground → among the strongest
- ·Among the strongest → gaining ground
- ·Gaining ground → among the strongest
- ·Among the strongest → gaining ground
- ·Gaining ground → among the strongest
Related sectors
Track pharmaceutical against the whole market
Zensei Edge maps 100+ sectors and themes against the S&P 500 — with the stocks inside each one, rotation history and alerts when leadership changes hands.